Somewhat Favorable Media Coverage Somewhat Unlikely to Affect PerkinElmer (PKI) Stock Price

Media stories about PerkinElmer (NYSE:PKI) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PerkinElmer earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 48.3273144557671 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Several equities research analysts have recently commented on the company. Cantor Fitzgerald restated a “hold” rating on shares of PerkinElmer in a research note on Sunday, July 16th. Piper Jaffray Companies restated a “buy” rating and set a $81.00 price target on shares of PerkinElmer in a research note on Friday, August 4th. Robert W. Baird restated a “buy” rating and set a $72.00 price target on shares of PerkinElmer in a research note on Friday, October 20th. Citigroup Inc. restated a “buy” rating and set a $80.00 price target (up previously from $74.00) on shares of PerkinElmer in a research note on Tuesday, September 26th. Finally, Cowen and Company restated a “hold” rating and set a $70.00 price target on shares of PerkinElmer in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $68.14.

Shares of PerkinElmer (NYSE:PKI) opened at 71.83 on Tuesday. The company’s 50 day moving average price is $70.08 and its 200-day moving average price is $66.05. The firm has a market cap of $7.92 billion, a price-to-earnings ratio of 21.66 and a beta of 0.72. PerkinElmer has a 1-year low of $45.35 and a 1-year high of $72.82.

PerkinElmer (NYSE:PKI) last announced its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $547.00 million for the quarter, compared to analyst estimates of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. PerkinElmer’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. Equities analysts expect that PerkinElmer will post $2.88 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio is 8.46%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

What are top analysts saying about PerkinElmer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PerkinElmer Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit